Shares of Bone Biologics Co. (OTC:BBLG – Get Free Report) dropped 11.7% during mid-day trading on Wednesday . The company traded as low as $4.85 and last traded at $4.91. Approximately 59,228 shares traded hands during trading, an increase of 84% from the average daily volume of 32,149 shares. The stock had previously closed at $5.56.
Bone Biologics Price Performance
The stock has a market cap of $16.06 million, a PE ratio of -0.10 and a beta of 0.75. The stock has a 50-day simple moving average of $4.49 and a 200-day simple moving average of $5.49.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Featured Stories
- Five stocks we like better than Bone Biologics
- 3 Fintech Stocks With Good 2021 Prospects
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- Technology Stocks Explained: Here’s What to Know About Tech
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.